Basic Information
Symbol
circUBAP2
RNA Class
circRNA
Alias
Ubiquitin Associated Protein 2
KIAA1491
RNA Polymerase II Degradation Factor UBAP2
Ubiquitin-Associated Protein 2
BA176F3.5
FLJ22435
UBAP-2
AD-012 Protein
Location (GRCh37)
9:33817819-34048885
UCSC Genome Browser
Location (GRCh38)
9:33817821-34048887
Host gene
UBAP2
Host category
mRNA
Forensic tag(s)
Sudden cardiac death diagnosis
External database
Transcripts
| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_UBAP2_0000800 | Exon-Exon | chr9:33922685-34017187 | chr9:33922687-34017189 | 260 nt | 0.5846 |
| hsa_UBAP2_0000900 | Exon-Exon | chr9:33922964-33923912 | chr9:33922966-33923914 | 392 nt | 0.5612 |
| hsa_UBAP2_0001100 | Exon-Exon | chr9:33923184-33924282 | chr9:33923186-33924284 | 187 nt | 0.5455 |
| hsa_UBAP2_0001300 | Exon-Exon | chr9:33923377-33923998 | chr9:33923379-33924000 | 106 nt | 0.6038 |
| hsa_UBAP2_0001400 | Exon-Exon | chr9:33923377-33924282 | chr9:33923379-33924284 | 79 nt | 0.5190 |
| hsa_UBAP2_0001500 | Exon-Exon | chr9:33923377-33956144 | chr9:33923379-33956146 | 168 nt | 0.5536 |
| hsa_chr9_0415100 | Intergenic-Intergenic | chr9:33923498-33923725 | chr9:33923500-33923727 | 228 nt | 0.5263 |
| hsa_UBAP2_0001900 | Exon-Exon | chr9:33924204-33941779 | chr9:33924206-33941781 | 79 nt | 0.5190 |
| hsa_UBAP2_0002200 | Exon-Exon | chr9:33926615-33927990 | chr9:33926617-33927992 | 140 nt | 0.6071 |
| hsa_UBAP2_0002300 | Exon-Exon | chr9:33926615-33932626 | chr9:33926617-33932628 | 644 nt | 0.5901 |
Showing 101 to 110 of 263 entries
Forensic Context
A review of literature indicates that the circUBAP2 is an oncogenic circular RNA upregulated in osteosarcoma patient samples, where its high expression is correlated with lower overall survival and promotes tumor growth while inhibiting apoptosis [Di Agostino et al. DOI:10.3389/fcell.2020.00389]. A study in human patients with heart failure after acute myocardial infarction demonstrated that the expression level of the circUBAP2 was not significantly different between patients with sacubitril/valsartan resistance and non-resistant patients in quantitative real-time PCR validation [Su et al. DOI:10.1016/j.ejphar.2023.175547].